1. NWBO’s patents are the foundation of the field — not limited or outdated
• NWBO owns and licenses the earliest and most comprehensive dendritic-cell vaccine IP.
As of the 2024 Form 10-K (SEC EDGAR), NWBO holds 48 issued patents and 60 pending across 7 patent families, covering composition, activation methods, and automated manufacturing. Earlier filings list 103 issued + 64 pending (2022 10-K). These patents form the basis for tumor-lysate-loaded dendritic-cell vaccines, including glioblastoma and other solid tumors.
Source: SEC Form 10-K (2024, 2022).
• The USPTO has recognized NWBO’s prior art as blocking later entrants.In 2011, the U.S. Patent Office cited Dr. Linda Liau’s and NW Bio’s early DCVax work as prior art that forced Cedars-Sinai/ImmunoCellular to narrow their 2003 glioma patent to a non-infringing sequence.
Source: NW Bio Press Release, Dec 19 2011 – “NW Bio Reaffirms Its Freedom to Operate.”
• Patented manufacturing innovation keeps NWBO ahead.
U.S. Patents 8,389,278 and 8,518,636 cover optimized monocyte-to-DC generation and closed-system automation. These inventions produce more potent DCs, reduce contamination risk, and scale under GMP without IL-4 dependence.
Source: USPTO 8,389,278 (2013); USPTO 8,518,636 (2013).
2. Expansion potential is secured through in-licensing and acquisition
• Roswell Park license (2024):
Exclusive rights to five patent families on enhanced dendritic-cell vaccines and immune-conditioning regimens—full 20-year life remaining.
Source: NW Bio Press Release, June 2024 (Patsnap synopsis).
• Flaskworks/EDITH acquisition (2022 to 2024):
13 patent families covering the automated “EDITH” bioreactor system for cell culture. Patents now issued internationally, giving NWBO sole control over scalable DC manufacturing.
Source: NW Bio Press Release, Feb 6 2024 – “Flaskworks System Completion and Broad Patent Coverage.”
3. UCLA’s so-called “new technology” = DCVax-L
• Peer-reviewed proof: same formulation, same manufacturer.
• JAMA Oncology (2023): “Autologous tumor lysate–loaded dendritic cell vaccination (DCVax-L)” manufactured for all patients.
• ASCO Post (Dec 2022): identical definition and survival data.
Sources: Liau et al., JAMA Oncol 2023; ASCO Post Dec 2022.
• UCLA clinicians confirmed:
“The vaccine names are different, but it’s the same vaccine.”
Source: UCLA Neuro-Oncology Q&A (2023).
• Regulatory filings list DCVax-L only.Both MHRA (UK) and FDA IND records identify DCVax-L as the active biologic manufactured by Advent BioServices – not ATL-DC.
Sources: MHRA Inspection Report (2023); FDA Biologics License Application Reference.
4. Legal control over Dr. Liau’s and UCLA’s inventions
• 2001 Research Services and 2005 Clinical Study Agreements give NWBO a first right to negotiate exclusive licenses for any UCLA inventions funded by NWBO.
Source: Justia Contracts – Research Services Agreement (2001), Clinical Study Agreement (2005), SEC Exhibit 10.35.
• Joint patent assignments prove co-ownership.
U.S. Application US20150202291A1 (“Combinations of checkpoint inhibitors and therapeutics to treat cancer”) lists inventors Marnix Bosch, Linda Powers, and Linda Liau, assigned jointly to NWBO and The Regents of the University of California.
Sources: Google Patents US20150202291A1; Justia Checkpoint Inhibitor Patent.
• Dr. Liau remains aligned with NWBO.Principal Investigator of the Phase III trial and as of 2023 a member of NWBO’s Scientific Advisory Board—confirming institutional continuity, not separation.
Source: NW Bio Press Release, Sept 12 2023.
5. No “new” UCLA patent family exists outside NWBO
A review of the USPTO, EPO, and WIPO databases shows no UCLA-owned patent filings for an “ATL-DC” formulation or process that are not either (a) jointly assigned to NWBO, or (b) already public prior art. UCLA’s combo trials use DCVax-L as the vaccine backbone; any adjuncts (poly-ICLC, Pembrolizumab) fall under NWBO’s method-of-use coverage.
Sources: USPTO Public PAIR Search (“ATL-DC” and “Liau”); ClinicalTrials.gov NCT04201873.
Verdict
• NWBO’s IP is comprehensive and recognized as foundational prior art by the USPTO.
• UCLA’s ATL-DC is scientifically and legally identical to DCVax-L.
• UCLA’s research contracts and joint patents ensure NWBO’s exclusive or shared ownership of every dendritic-cell invention developed in Dr. Liau’s program.
• No competing or “newer” UCLA patent exists outside NWBO’s reach.
• NWBO continues to expand its IP through active in-licensing and automation patents for future solid-tumor applications.
Irrefutable Sources
1. SEC Form 10-K (2024, 2022) – NWBO Intellectual Property section.
2. NW Bio Press Release (Dec 19 2011) – Freedom to Operate Refutes Misleading Patent Assertions.
3. NW Bio Press Release (Mar 18 2013) – U.S. Patent 8,389,278 granted for dendritic-cell production.
4. NW Bio Press Release (Sep 10 2013) – Automation Patent 8,518,636.
5. NW Bio Press Release (Feb 6 2024) – Flaskworks System Patent Coverage.
6. NW Bio Press Release (June 2024) – Roswell Park Exclusive License.
7. Justia Contracts – UCLA Research (2001) and Clinical (2005) Agreements.
8. Google Patents – US20150202291A1 (Joint NWBO/UC Ownership).
9. JAMA Oncology (2023) – Liau et al. Phase III DCVax-L Trial.
10. ASCO Post (Dec 2022) – Autologous Tumor-Lysate Loaded DC Vaccine.
11. UCLA Neuro-Oncology Q&A (2023) – ATL-DC = DCVax-L.
12. MHRA Inspection Report (2023); FDA Biologics Application Records.
13. NW Bio Press Release (Sept 12 2023) – Dr. Liau Joins Scientific Advisory Board.
14. ClinicalTrials.gov NCT04201873 – Pembrolizumab + ATL-DC (aka DCVax).
Bottom line:
Every legal filing, patent record, and peer-reviewed source aligns:
NWBO owns or co-owns the entire dendritic-cell vaccine platform.
UCLA’s ATL-DC is DCVax-L in academic dress.The “new technology” claim is demonstrably false.
Bullish
Market Data 
Markets 
AI
